Previous studies reported that WES reveals high-risk frameshift mutations and somatic mutations for PABPC3 in breast cancer patients [19,20] and malignant ovarian germ cell tumors, respectively [21]. This evidence concerns the gene PABPC3 and breast carcinoma.